Stocks to Watch today, December 15, 2025: Indian equities are set for a weaker start on Monday, tracking negative global cues ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled ‘Investigation ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently completed a study titled ‘Efficacy ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in ...

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

Danish pharmaceutical giant Novo Nordisk has introduced its type 2 diabetes treatment, Ozempic, in India. Positioned as a ...

Dozens of units of counterfeit Ozempic (semaglutide 1mg injection) were seized by the FDA, according to a drug safety alert issued by the Agency.

A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...

Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...